Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipid Lowering Therapy in Melanoma Patients on Immune Checkpoint Inhibitors
NCT07704918Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Randomised, open-label trial of ulinastatin and ezetimibe in atherosclerosis (2 arms), sponsored by University of Colorado Denver. Primary endpoint: Mean change in LDL-C at 12 months. Started Oct 2026; status: recruiting.
02
Drugs
ulinastatinezetimibe
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT07704918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07704918.